Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01450826 | Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | completed | Phase 2 | 136 | Katy PetersOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT02157103 | A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | completed | Phase 2 | 3 | Emory UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | terminated | Phase 1 / Phase 2 | 1 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT01602588 | A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)(HCQ) | completed | Phase 2 | 54 | University College, LondonOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT02227576 | Prevention of Thrombocytopenia in Glioblastoma Patients(PLATUM) | terminated | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00076102 | Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00021541 | R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 2 | Apr 17, 2018 | clinicaltrials |
| NCT02945826 | uPAR-PET/MRI in Glioblastoma Multiforme | unknown | Phase 2 | 35 | Rigshospitalet, DenmarkOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT03242603 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells(NKEXPGD2) | unknown | Phase 1 / Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00003456 | Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003471 | Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma | terminated | Phase 2 | 7 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003474 | Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | terminated | Phase 2 | 3 | Musli Thyropeutics Ltd.INDUSTRY | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003472 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma | terminated | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00003535 | Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma | terminated | Phase 2 | 9 | Burzynski Research InstituteOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00200161 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | completed | Phase 2 | 127 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00047320 | Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors | completed | Phase 2 | 104 | Children's Oncology GroupNETWORK | 5 | Feb 14, 2018 | clinicaltrials |
| NCT00068250 | Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | completed | Phase 1 / Phase 2 | 60 | Radiation Therapy Oncology GroupNETWORK | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00766753 | Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 22 | Frank LiebermanOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00782756 | Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma | completed | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01632228 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | completed | Phase 2 | 135 | Hoffmann-La RocheINDUSTRY | 8 | Feb 5, 2018 | clinicaltrials |
| NCT00619112 | Temozolomide in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 60 | University of California, San FranciscoOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02047214 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy | terminated | Phase 2 | 17 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02971319 | Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma | completed | Phase 2 | 32 | Proactina S.A.OTHER | 2 | Jan 26, 2018 | clinicaltrials |
| NCT01740570 | Phase I/II Cabazitaxel for Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT00003473 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas | completed | Phase 2 | 20 | Burzynski Research InstituteOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00458601 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme(ACT III) | completed | Phase 2 | 82 | Celldex TherapeuticsINDUSTRY | 1 | Jan 16, 2018 | clinicaltrials |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | terminated | Phase 1 / Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT03393689 | RGD PET/MRI in Sporadic Vestibular Schwannoma | unknown | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT03392714 | Bendamustine-based Combination Therapy for PCNSL | unknown | Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT00387790 | Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03390062 | A Study of Apatinib in Recurrent or Recurrent High-grade Glioma | unknown | Phase 2 | 30 | West China HospitalOTHER | 0 | Jan 4, 2018 | clinicaltrials |
| NCT03388372 | Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | completed | Phase 2 | 39 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00895180 | Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT02977689 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Dec 20, 2017 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT03356600 | Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer | unknown | Phase 2 | 44 | Shanxi Province Cancer HospitalOTHER | 0 | Dec 11, 2017 | clinicaltrials |
| NCT03366376 | Hippocampus-sparing WBRT and Simultaneous Integrated Boost for Multiple Brain Metastases From NSCLC(KROG17-06) | unknown | Phase 2 | 80 | Samsung Medical CenterOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00362570 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | completed | Phase 2 | 1 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jul 2, 2018source: clinicaltrials